Vers13/1 FINAL PROGRAM pitta 1 Vers13/1 FINAL PROGRAM ORGANIZING COMMITTEE CONFERENCE CENTRE Z. BASHIR (UK) G. BATTAGLIA (ITALY) M. BEAR (USA) D.V. BRUNO (ITALY) G. COLLINGRIDGE (UK) J. CONN (USA) A. COPANI (ITALY) F. FERRAGUTI (AUSTRIA) P. FLOR (SWITZERLAND) F. GASPARINI (SWITZERLAND) R. GEREAU IV (USA) K. HUBER (USA) Grande Albergo Capotaormina Via Nazionale, 105 98039 Taormina (Messina – Italy) Phone: +39.0942.57.21.11 Fax: +39.0942.62.54.67 www.capotaorminahotel.com M. KANO (JAPAN) S. MACCARI (FRANCE) J. MONN (USA) R. NGOMBA (ITALY) J.P. PIN (FRANCE) R. NISTICO’ (FRANCE) T. SALT (UK) D.D. SCHOEPP (USA) M. WATANABE (JAPAN) M. ZHUO (CANADA) S. ZUKIN (USA) SCIENTIFIC SECRETARIAT ORGANIZING SECRETARIAT Ferdinando Nicoletti M.D. Dept. Of Human Physiology and Pharmacology University of Rome “La Sapienza” Piazzale Also Moreo, 5 -00185 ROMA Italy Phone: +39.06.49.91.29.69 Fax: +39.06.44.50307 E.mail; ferdinandonicoletti@hotmail.com E.mail: nicoletti@neuromed.it Centro Organizzazione Congressi Via Miss Mabel Hill, 9 98039 Taormina (Messina – Italy) Phone; +39.0942.242.93 Fax: +39.0942.242.51 E.mail: info@mglu.it DATE TO REMEMBER MEETING WEB SITE Deadline for abstract submission www.mglu.it June 15, 2014 In the web site you will find all relevant information Deadline for registration fee on the Meeting on program as well congress June 15, 2014 registration and hotel accommodation. Deadline for hotel reservation The website will be kept up-to-date in the months June 15, 2014 months leading up to the Meeting. Deadline for hotel cancellation with refund June 20, 2014 Deadline for registration cancellation with refund June 20, 2014 No refund will be made for cancellations received after June 20th, 2014 2 Vers13/1 FINAL PROGRAM Sunday, September 28th OPENING SYMPOSIUM P.M. Chair: J.P. Pin (France) an D.D. Schoepp (USA) 4.30 4.55 Structure and function studies of the mGlu5 receptor in the design of novel negative allosteric modulators K.A. Bennett, A.S. Doré, K. Okrasa, J.C. Patel, M. Serrano-Vega, R. M. Cooke, J. C. Errey, A. Jazayeri, , B. Tehan, G.R. Wiggin, J.A. Christopher and F.H. Marshall (UK) 4.55 5.20 Cryo-EM visualization of a metabotropic glutamate receptor G. Skiniotis (USA) 5.20 5.45 Time-Resolved Fluorescent Sensors as powerful High Throughput Screening tools for Metabotropic Glutamate Receptors E. Trinquet (France) 5.45 6.10 Functional organization and dynamics of mGluR transmembrane domains P. Rondard (France) 6.10 6.35 Optical analysis of receptor activation and signaling M.J. Lohse (Germany) 6.35 7.00 Optical dissection of mGluR function E. Isacoff (France) 7.00 7.25 Optical Control of metabotropic glutamate receptor with photoswitchable drugs A. Llebaria, S. Pittolo, X. Gómez-Santacana, K. Eckelt, X. Rovira, J. Dalton, C. Goudet, J.-P. Pin, A. Llobet, J. Giraldo and P. Gorostiza (Spain and France) 7.25 7.50 Fine tuning of sub-millisecond conformational dynamics controls mGluR agonist efficacy J.P. Pin, L. Olofsson, S.Felekyan, E. Doumazane,P.Scholler, L.Fabre, J.M. Zwier, P. Rondard, C.A.M. Seide and E. Margeat (France and Germany) 3 Welcome cocktail at Grande Albergo CapoTaormina Vers13/1 FINAL PROGRAM Monday, September 29th morning session MOLECULAR AND FUNCTIONAL CHARACTERIZATION Chair: J. Bockaert (France) and P. Worley (USA) 8.00 8.25 A genetic dissection of synaptic glutamate receptor function R. Nicoll (USA) 8.25 8.50 Gating of the orphan GluD2 receptor by the mGlu1 receptor L. Fagni (France) 8.50 9.15 A role for Pin1 prolyl isomerase in group 1 mGluR signaling P. Worley (USA) 9.15 9.40 Regulation of Metabotropic Glutamate Receptor function by interacting proteins. A. Francesconi (USA) 9.40 10.05 Surprising Consequences of metabotropic glutamate receptor heteromerization P.J. Kammermaier (USA) 10.05 10.30 Coffee break 10.30 10.55 Molecular Mechanisms Regulating Group I Metabotropic Glutamate Receptors K. Roche (USA) 10.55 11.20 Presynaptic release-regulating mGlu receptors: un update A. Pittaluga (Italy) 11.20 11.45 mGluR1 modulates the production of exosomes in melanoma cells S. Chen, A. L. Isola, Y. Wen and J. Goydos (USA) 11.45 12.10 4 Signal transduction of mGlu1 receptors in neurons and cancer cells J.T. Wroblewski (USA) Working lunch Monday, September 29th afternoon session FUNCTIONAL ANATOMY Chair: F. Ferraguti (Austria)and R. Shigemoto (Austria) 3.15 3.40 The synaptic targeting of mGluR1 by its carboxyl-terminal domain is crucial for cerebellar function A. Aiba (Japan) 3.40 4.05 Distinct mechanisms of short- and long-term motor learning in the cerebellum R. Shigemoto (Austria) 4.05 4.30 Synapse-specific molecular imaging at the nanoscale in intact brain circuits I . Katona (Hungary) 4.30 4.55 Role of Metabotropic Glutamate receptor 2/3 in hippocampal temporo-ammonic pathand cross talk with the Gabaergic and Cholinergic systems S. Gatti, T.M. Ballard, M. Lorez, M. Kessler, J. Messer, J. Wichmann, J.G.Wettstein, B. Biemans, C. Risterucci and F. Knoflach (Switzerland) 4.55 5.15 Coffee break Vers13/1 FINAL PROGRAM 5.15 5.40 Is there a Master Plan for the specific expression of group III mGlu receptors in distinct presynaptic axon terminals? F. Ferraguti (Austria) 5.40 6.05 Burst firing in the mediodorsal thalamus and related cognitive circuits is modulated by metabotropic glutamate receptors C.S. Copeland, S.A. Neale and T.E. Salt (UK) Monday, September 29th afternoon session MGLU RECEPTORS AND KYNURENINES Chair: R. Schwarcz (USA) and V. Bruno (Italy) 6.05 6.30 Kynurenine Pathway Metabolites as Modulators of Glutamatergic Neurotransmission R. Schwarcz, K.V. Sathyasaikumar, M. Tararina, H.-Q. Wu, D.M. Bortz and J.P. Bruno (USA) 6.30 6.55 Reduced levels of xanthurenic acid in the blood of schizophrenic patients F. Fazio, L. Lionetto, M. Curto, F. Napolitano, G. Vignaroli, M. Capi, V. Corigliano, A. Comparelli, L. Iacovelli, G. Mauro, V. Bruno, G. Battaglia, P. Girardi, M. Simmaco, F. Nicoletti (Italy) 6.55 7.20 Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice F. Fallarino, F. Fazio , C. Zappulla, S.Notartomaso, C.Busceti, A. Bessede , P. Scarselli , C. Vacca , M. Gargaro , M. Allegrucci , L. Lionetto , M. Simmaco, M. L. Belladonna and F. Nicoletti (Italy and France) Buffet Dinner in Taormina – Hotel Timeo Performance at the Greek Theatre Tuesday, September 30th morning session DRUG ADDICTION Chair: A. Markou (USA) and P. Kalivas (USA) 8.00 8.25 Neural mechanisms of reward and aversion R. Malenka, S. Lammel, E. Steinberg, N. Wall and K. Beier (USA) 8.25 8.50 Targeting mGluR1 to reverse cocaine-induced plasticity and decrease craving M.E. Wolf, J.A. Loweth, A.F. Scheyer and K.Y. Tseng (USA) 8.50 9.15 Synaptopathies of the mGlu signalosome O.J. Manzoni, H.G.S. Martin, A. Bilbao, D. Neuhofer, O. Lassalle, A. Thomazeau and R. Spanagel (France and Germany) 9.15 9.40 Development of a viral construct expressing a light-activated mGluR5 receptor (OptoXR-mGluR5) for optogenetic applications M. F. Olive, C. Ramakrishnan, L. Fenno and K. Deisseroth (USA) 9.40 10.05 mGlu5 receptors & extinction of drug-seeking A. J. Lawrence (Australia) 10.05 10.25 Coffee break 5 Vers13/1 FINAL PROGRAM 10.25 10.50 Using Glial Release of Glutamate onto mGluRs to Control Relapse to Drug Use P. W. Kalivas, M.D. Scofield and C.D. Gipson (USA) 10.50 11.15 Design, Synthesis and Characterization of Small Molecule Group II Metabotropic Glutamate Receptor Allosteric Modulators N. Cosford (USA) 11.15 11.40 Presynaptic mGluR2 and mGluR7 receptors critically modulate psychostimulant dependence A. Markou, X. Li, A. Stoker, D.J. Sheffler, P.J. Conn and N.D.P. Cosford (USA) 11.40 12.05 Mechanisms Underlying the mGluR2 Autoreceptor Function and its Role in Control of Alcohol Drinking D.M. Lovinger, Z. Zhou, M. Heilig and D. Goldman (USA) Working lunch Tuesday, September 30th afternoon session DEVELOPMENT PLASTICITY AND DISORDER OF SYNAPTIC FUNCTION Chair: M. Kano (Japan) and M. Watanabe (Japan) 3.00 3.25 Requirement of mGluR1 for experience-dependent remodeling of mouse retinogeniculate synapses M. Kano, M. Narushima, M. Uchigashima, M. Watanabe, A. Aiba and M. Miyata (Japan) 3.25 3.50 mGluR1 sculpts heterologous inputs to cerebellar Purkinje cells M. Watanabe and R. Ichikawa (Japan) 3.50 4.15 mGlu1 Receptors epigenetically suppresse mGlu5 Receptors in the cerebellum S. Notartomaso, C. Zappulla, G. Mascio, M. Motolese, M. Cannella, P.Scarselli, R. Gradini, G. Battaglia, V. Bruno, F. Nicoletti (Italy) 4.15 4.40 Coordination between translation and degradation regulates inducibility of mGluR-LTD P. E. Castillo, M. E. Klein and B. A. Jordan (USA) 4.40 5.05 Role of Metabotropic and Ionotropic Glutamate Receptor signaling in activity-dependent spine shrinkage K. Zito, W.C .Oh, I.S. Stein, L.K. Parajuli, and T.C. Hill (USA) 5.05 5.25 Coffee break Tuesday, September 30th afternoon session SYNAPTIC PLASTICITY AND COGNITIVE FUNTIONS Chair: G. Collingridge (UK) and Z. Bashir (UK) 5.25 5.50 Visualization of AMPA Receptor Synaptic Plasticity In Vivo R. L. Huganir (USA) 5.50 6.15 mGlu2 receptors: are they needed? D. Lodge, M. Byrne, L. Ceolin, S.L. Choi, B. Conway-Campbell, M. Mercier, C. Nicolas, E. Robinson and C. Wood (UK) 6.15 6.40 GluA2 and actin regulation of mGluR-dependent long-term depression in the hippocampus Z. Jia (Canada) 6 Vers13/1 FINAL PROGRAM 6.40 7.05 Involvement of mGlu5 in synaptic information processing in the CA3 region in vivo: the key to pattern completion? D. Manahan-Vaughan and H. Hagena (Germany) 7.05 7.30 Disrupted cross-laminar cortical processing in β-amyloid pathology precedes cell death K. G. Reymann (Germany) 7.30 7.55 mGlu1 receptor-induced LTD of NMDA receptor transmission selectively at Schaffer collateral-CA1 synapses mediates metaplasticity Z.I. Bashir, M. Bhouri, P. A. Farrow, A. Motee, X. Yan, G. Battaglia, L. Di Menna, B. Riozzi, F. Nicoletti and S. M. Fitzjohn (UK and Italy) 7.55 8.20 mGluR5 and Amyloid-beta mediated aberrant synaptic plasticity and object cognition deficit K. Cho (UK) 8.20 8.45 mGluR2 Negative Allosteric Modulators compare favorably to standard of care with respect to pro-cognitive effects in rhesus monkey J. M. Uslaner (USA) Tuesday, September 30th evening session POSTER SESSION 9.00PM ALCANTARA ROOM Sicilian Dinner buffet at Grande Albergo Capotaormina Wednesday, October 1st morning session MGLU AND DEPRESSION/ANXIETY Chair: S. Chaki (Japan) and A. Pilc (Poland) 7.45 8.10 Potential of mGlu2/3 receptor antagonists for treatment-resistant depression: comparison with ketamine S. Chaki (Japan) 8.10 8.35 Efficacy and Safety of a Novel mGlu2 Receptor Positive Allosteric Modulator as an Adjunctive Treatment to an SSRI/SNRI in the Treatment of Anxious Depression J.M. Kent, E. Daly, M. Ceusters, I. Kezic, R. Lane, P. Lim, H. De Smedt, P. De Boer, L. Van Nueten, and W. Drevets (USA and Belgium) 8.35 9.00 Acetyl-L-carnitine as a novel proneurogenic and antidepressant drug: contribution of mGlu2 receptors M. Grilli, B. Cuccurazzu, V. Bortolotto, M.M. Valente, A. Koverech and P.L. Canonico (Italy) 9.00 9.25 Targeting the epigenetic control of mGlu2 to reverse the stress-induced loss of resilience: implications for next-generation psychiatric treatments C. Nasca, B. Bigio, D.Zelli and B.S. McEwen (USA) 9.25 9.50 The opposing efficacy of mGlu receptor agonists and antagonist in depression vs. schizophrenia A. Pilc, A. Pałucha-Poniewiera and J.M. Wierońska (Poland) 9.50 10.10 Coffee break 10.10 10.35 Potential utility of full and partial mGlu5 NAMs in major depression and addictive disorders J. Rook (USA) 10.35 11.00 Discovery of the mGlu5 negative allosteric modulator basimglurant (RO4917523) G. Jaeschke, S.Kolczewski, E. Vieira, B. Büttelmann, J. Huwyler, J.U. Peters, E. Prinssen, A. Ricci, D. Rueher, M. Schneider, P. Spurr, D. Tännler, J. Wichmann, J.G. Wettstein, R. Porter, W. Spooren, L. Lindemann (Switzerland) 7 Vers13/1 FINAL PROGRAM Wednesday, October 1st morning session PAIN Chair: M. Zhuo (Canada)and V.Neugebauer (USA) 11.00 11.25 Pain-related mGluR modulation of medial prefrontal cortex-amygdala interactions V. Neugebauer, G. Ji and T. Kiritoshi (USA) 11.25 11.50 Metabotropic glutamate receptor (mGluR) dependent synaptic plasticity in pain-related cortex and their roles in chronic pain M. Zhuo (Canada) 11.50 12.15 Broad spectrum efficacy with LY2969822, a metabotropic glutamate2/3 agonist prodrug of LY2934747, in rodent pre-clinical pain models. M.P. Johnson, M.A. Muhlhauser, E. Nisenbaum, R.M.A. Simmons,B. Forster, K.L. Knopp, L. Yang, D. Morrow, D.L. Li, J.D. Kennedy, and J.A. Monn (USA) 12.15 12.40 Fenobam: a clinical tool compound for assessment of the role of mGlu5 in human pain processing L.F. Cavallone, M.C. Montana, K. Frey, M. Wages, K. Regina and R.W. Gereau IV (USA) 12.40 13.05 N-acylethanolamines modulate glutamate transmission in the prelimbic cortex of neuropathic mouse S. Maione, L. Luongo, R. Romano, F. Guida, S. Boccella, F. Napolitano, V. de Novellis and A. Usiello (Italy) Working lunch Wednesday, October 1st afternoon session PHARMACOLOGY AND DRUG DEVELOPMENT Chair : J. Monn (USA) and F. Acher (France) 3.00 3.20 LY2491503, A Novel mGluR1 Antagonist for Persistent Pain: From Clone to Clinic E.S.Nisenbaum, S. Iyengar, K.L. Knopp, R.M. Simmons, D. Li, M.J. Fisher, S. Kuklish, V.N. Barth, M.G. Chambers, B.A. Heinz, S.A. Monk, P. Zanotti-Fregonara, J-S Liow, R. Xu, V.W. Pike, R.B. Innis and L.A. Arendt-Nielsen (Denmark and USA) 3.20 3.40 LY2934747: In Vitro and In Vivo Characterization of a Novel mGlu2/3 Receptor Agonist D. McKinzie, B. Heinz, X. Wang, D. Schober, C. Felder, H. Sanger, R. Vivier, E. Siuda, E. Nisenbaum, L. Thompson, B. Johnson, K. Knitowski, D. Shaw, L. Rorick-Kehn, J. Katner, K. Perry, M. Johnson, C. Beadle, S. Atwell, F. Lu, D. Clawson, M. Bures, S. Swanson and J. Monn (USA and UK) 3.40 4.00 Discovery and early clinical evaluation of a novel mGlu2 Receptor Positive Allosteric Modulator P. De Boer, H. Lavreysen, I. Kezic, M. Ceusters, H.De Smedt, L. Van Nueten, W. Drevets and J.M. Kent (Belgium and USA) 4.00 4.20 Discovery of LY3020371, a potent and selective mGlu2/3 receptor antagonist, for the treatment of depression J.M. Witkin and J.A. Monn (USA) 4.20 4.40 Discovery of novel mGlu3-selective allosteric modulators provides new insights into mGlu3 function C. Wenthur (USA) 4.40 5.00 Coffee break 8 Vers13/1 FINAL PROGRAM 5.00 5.20 New orthosteric group-III mGluR ligands F.C. Acher, B. Commare, I. Brabet, D. Rigault, Bertrand H.-O., C. Goudet and J.-P. Pin (France) 5.20 5.40 Supra-Physiological Pharmacology by mGlu4 Receptor Positive Allosteric Modulators X. Huang, M. D. Collins, N. J. Boyle, H. Zhang, E. Dale, M. Jørgensen, C. Bundgaard, L. K. Isaac, M. H. Schmidt, H. Zhong, F. C. Acher, R. M.Brodbeck and D.Doller (USA, Denmark and France) 5.40 6.00 The Discovery and Preclinical Characterization of the Novel mGluR5 Negative Allosteric Modulator PF470: Implications for Mechanism-based Toxicity? C. L. Shaffer (USA) 6.00 6.20 Progress Towards Novel Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators for CNS disorders S. Célanire (Switzerland) Wednesday, October 1st afternoon session REGULATION OF THALAMO-CORTICAL NETWORK Chair: J. Huguenard (USA) and R. Ngomba (Italy) 6.20 6.45 mGlu2 Receptors and sensory processing in the thalamus; a tale of astrocytes and neurones T.E. Salt, C.S Copeland, H.R. Parri, T.M. Wall, S.A. Neale and E. Nisenbaum (UK and USA) 6.45 7.10 Role of thalamic mGluRs in EEG rhythms of wake and sleep V. Crunelli (UK) 7.10 7.35 Modulation of Extrasynapitic GABAA Receptors by mGLU Receptors G. Di Giovanni, V. Crunelli and A. C. Errington (Malta and UK) 7.35 8.00 Group III metabootropic receptors modulate synaptic plasticity in the corticothalamic circuit J. Huguenard and C. Kyuyoung (USA) 8.00 8.25 Is there a future for Group I PAMs in epilepsy? G. Van Luijtelaar and R. Ngomba (The Netherlands and Italy)) 9 Beach party at Grande Albergo Capotaormina Vers13/1 FINAL PROGRAM Thursday, October 2nd morning session SCHIZOPHRENIA Chair: J.Conn (USA) and F. Matrisciano (USA) 7.45 8.10 Targeting glutamate neurotransmission for prevention of psychosis B. Moghaddam (USA) 8.10 8.35 Allosteric modulator effects and physiological roles of mGlu receptor heterodimers in identified brain circuits P. J. Conn, A. Ghoshal, X. Xiang, J.M. Rook, C.W. Lindsley, S. Yen, C.K. Jones, and C.M. Niswender (USA) 8.35 9.00 DNA methylation and hydroxymethylation in psychiatric disease. D.R. Grayson and A. Guidotti (USA) 9.00 9.25 Structural insights into the crosstalk mechanism between 5-HT2A and mGlu2 receptors in schizophrenia J. González Maeso (USA) 9.25 9.50 Functional brain imaging of experimental Group II metabotropic glutamate receptor (mGluR) agonists LY2979165 and LY2140023 in healthy human subjects A. J. Schwarz, A. Schmechtig, J. McColm, K. Jackson, C. Brittain, C. Gonzales, S. Suriyapperuma, J. Foster, S. Tauscher-Wisniewski, B. Kinon and M.A. Mehta (USA) 9.50 10.10 Coffee break 10.10 10.35 The development of pomaglumetad methionil as a glutamate-based pharmacotherapy for schizophrenia: lessons learned V. L. Stauffer (USA) 10.35 11.00 Glutamate Receptors genes and schizophrenia M. Gennarelli and E. Sacchetti (Italy) Thursday, October 2nd morning session NEURODEVELOPMENT/AUTISM Chair: W. Spooren (Switzerland) and B.K. Kaang (Korea) 11.00 11.25 EU-AIMS: mGlu1 from mouse to patient D. Murphy (UK) 11.25 11.50 mGluR5 as a Fragile X Treatment Target M.R. Tranfaglia (USA) 11.50 12.15 mGluR4 and psychiatric disorders B. Biemans and G. Jaeschke (Switzerland) 12.15 12.40 Glutamate receptors and autism B.K. Kaang (Korea) Working lunch 10 Vers13/1 FINAL PROGRAM Thursday, October 2nd afternoon session AUTISM Chair: K. Huber (USA) and M.V. Catania (Italy) 3.00 3.25 Targeting MAP-kinase interacting kinases restores protein synthesis homeostasis and improves behavioral deficits in neuroligin-3 mouse model of autism S. Baudouin, L. Burkle and P. Scheiffele (Switzerland and UK) 3.25 3.50 Regulation of mGluR5-Homer scaffolds in Fragile X Syndrome mice K.M. Huber, W. Guo, K.A. Collins, G. Molinaro and P. F. Worley (USA) 3.50 4.15 Dysfunctions of metabotropic glutamate receptor subtype 5 (mGlu5) receptors in a mouse model of Fragile X syndrome M.V. Catania, M. Spatuzza, E. Aloisi, S. D’Antoni, J.P. Dupuis, L Costa, C. M. Bonaccorso, G. Molinaro, G. Battaglia, S. Musumeci, L. Davidovic, B. Bardoni, L. Ciranna, F. Nicoletti, L. Groc and A. Frick (Italy and France) 4.15 4.40 Activity-dependent Arc expression: mechanism, function and application H. Bito (Japan) 4.40 4.55 Coffee break 4.55 5.20 Mutations of the SHANK genes and alterations of mGlu5 signaling C. Sala, C. Verpelli, C. Vicidomini and D.I. Orellana (Italy) 5.20 5.45 Aberrant cofilin signaling in a mouse model of Fragile X syndrome S. Zukin (USA) 5.45 6.10 Synaptic and Circuit Mechanisms for Striatal mGluR5 Signaling in Compulsive Behaviors N. Calakos (USA) 6.10 6.35 Metabotropic glutamate receptor 7: a novel target for the treatment of Rett Syndrome C.M. Niswender, R. Klar, R.G. Gogliotti, R. Zamorano, A.G. Walker, Z. Xiang and P.J. Conn (USA) 6.35 7.00 Structural Plasticity of Dendritic Spines During Long-Term Depression M. Bosch and M. Bear (USA) 7.00 7.25 Facilitating glutamate mGluR4 receptor signaling relieves autistic-like deficits in mice J. Le Merrer, J.A.J. Becker and B.L. Kieffer (France and Canada) Dinner at Taormina’s Garden Mediterranean buffet with music and cabaret 11 Vers13/1 FINAL PROGRAM Friday, October 3rd morning session EMERGING ROLES FOR MGLU7 AND MGLU8 RECEPTORS AS DRUG TARGETS IN NEURAL AND SOMATIC DISORDERS Chair: P. Flor (Germany) and J.F. Cryan (Ireland) 7.45 8.10 Therapeutic Potential of Orthosteric and Allosteric mGlu7 Receptor Drugs P. J. Flor, C.E. Gee, D. Peterlik, N. Uschold-Schmidt, J. F. Cryan, R. Bouhelal, M. Fendt, F. Gasparini, I. Vranesic, R. Glatthar and H. van der Putten (Germany and Ireland) 8.10 8.35 mGlu7: A therapeutic target for stress-related disorders of brain and gut J.F. Cryan (Ireland) 8.35 9.00 mGlu7 Receptor Modulation Relieves Behavioral and Physiological Consequences Induced by Chronic Psychosocial Stress N. Uschold-Schmidt D. Peterlik, A. Bludau, T. Killian, D. Grabski, S. O. Reber and P. J.Flor (Germany) 9.00 9.25 The last mGlu: Is mGlu8 a therapeutic target? R.M. Duvoisin and J. Raber (USA) 9.25 9.50 Role of mGlu7 and mGlu8 receptors in event learning M. Fendt (Germany) 9.50 10.10 Coffee break Friday, October 3rd morning session EXITOTOXICITY , BRAIN ISCHEMIA AND PARKINSON’S DISEASE Chair: G. Battaglia (Italy)and A. Copani (Italy) 10.10 10.35 Group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration P. Gressens (France) 10.35 11.00 mGluRs in stroke T. Wieloch (Sweden) 11.00 11.25 Role of ionotropic and metabotropic glutamate receptors in models of ischemic tolerance D.E. Pellegrini-Giampietro, E. Gerace, E. Zianni, F. Gardoni, T. Scartabelli, E. Landucci, F. Moroni, G. Mannaioni and M. Di Luca (Italy) 12 Vers13/1 FINAL PROGRAM 11.25 11.50 MGluR5 Antagonists and neuroprotection in Parkinson’s disease: An effect that extends beyond dopaminergic cell groups Y. Smith (USA) 11.50 12.15 Targeting metabotropic glutamate receptors (mGluRs) in Parkinson’s disease M. Amalric (France) 12.15 12.40 Preclinical and clinical evaluation of dipraglurant, a novel negative allosteric modulator (NAM) of the mGlu5 receptor for the treatment of dystonia and levodopa induced dyskinesia S. Poli (Switzerland) 12.40 1.05pm mGlu5 receptors in Parkinson’s disease and MPTP-lesioned monkeys: behavior and brain molecular correlates T. Di Paolo, N. Morin, B. Ouattara, L. Grégoire , M. Morissette, P. Samadi, F. Gasparini, A. Rajput , A. H. Rajput and B. Gomez-Mancilla (Canada and Switzerland) 1.05-1.30pm Antagonism of mGluR5 to treat L-DOPA-induced dyskinesia: when and how would this treatment work? M.A. Cenci (Sweden) 1.05 1.30pm mGluR3 PAM as novel neuroprotective therapeutic strategy for Parkinson’s Disease S. Schann (France) Working lunch 13 Vers13/1 FINAL PROGRAM SUMMARY SCHEDULE Symposium 1 (pag.3) Opening Symposium Sun, 2014-09-28 04.30pm-7.50pm Symposium 2(pag.4) Molecular and functional characterization Mon, 2014-09-29 08.00am-12.10am Symposium 3 (pag.4-5) Functional anatomy Mon, 2014-09-29 03.15pm-06.05pm Symposium 4 (pag.5) mGlu recepotrs and kynurenines Mon, 2014-09-29 06.05pm-07.20pm Symposium5 (pag.5-6) Drug addiction Tue, 2014-09-30 08.00.am -12.05am Symposium 6 (pag.6) Development plasticity and disorder of synaptic function Tue, 2014-09-30 03.00pm-05.05pm Symposium 7 (pag.6-7) Synaptic plasticity and cognitive functions Tue, 2014-09-30 05.25pm-08.45pm Poster session (pag.7)- Alcantara room Tue, 2014-09-30 09.00pm Symposium 8(pag.7-8) mGlu and depression/anxiety Wed, 2014-10-01 07.45am-11.00am Symposium 9 (pag.8) Pain Wed, 2014-10-01 11.00am-1.05pm Wed, 2014-10-01 03.00pm-06.20pm Symposium 11 (pag.9) Regulation of thalamo-cortical network Wed, 2014-10-01 06.20pm-08.25pm Symposium 12 (pag.9) Schizophrenia Thu, 2014-10-02 07.45am-11.00am Thu, 2014-10-02 11.00am-12.40am Symposium 14 (pag.11) Autism Thu, 2014-10-02 03.00pm-07.25pm Symposium 15 (pag.11) Emerging roles for mGlu7 and mGlu8 receptors as drug targets in neural and somatic disorders Fri, 2014-10-03 07.45am-09.50am Symposium 16 (pag.11-12) Exitotoxicity, brain ischemia and parkinson’s disease Fri, 2014-10-03 10.10am-01.30pm Symposium 10 (pag.8-9) Pharmacology and drug development Symposium 13 (pag.10) Neurodevelpment/Autism 14
© Copyright 2024 Paperzz